Quote:
Ōmura discovered a unique and extraordinary microorganism that could produce ivermectin in 1973 (Burg et al., 1979). Ivermectin was subsequently commercialized because it showed great safety and effectivity in human health. The current status of ivermectin was continuing to surprise and excite scientists (Laing, Gillan, & Devaney, 2017). It was originally intended to be a broad‐spectrum antiparasitic agent, and treat onchocerciasis, strongyloidiasis, lymphatic filariasis, and scabies in veterinary and human medicine (Chabala et al., 1980). There was an outstanding advantage of ivermectin that no confirmed or increased drug resistance appears in parasites, even in those human populations who have been receiving ivermectin as a monotherapy for more than 30 years (van Wyk & Malan, 1988). In terms of mechanism, the primary target of ivermectin is glutamate‐gated chloride channels (Abdeltawab et al., 2020). However, it was increasingly believed that ivermectin was closely related to the immune defense mechanism and acted like immunomodulatory agents to help suppress the parasite's ability to evade the host's immune (Schaller et al., 2017). Today, the new use of ivermectin made it become a relatively unknown drug. Drug repurposing and repositioning has been shown to control a completely new range of diseases (Ashour, 2019). For example, orbital myiasis, trichinosis, malaria, leishmaniasis, African trypanosomiasis, asthma, epilepsy, neurological disease, antiviral (e.g., human immunodeficiency virus [HIV], dengue, encephalitis; Yang et al., 2020), antibacterial (tuberculosis and Buruli ulcer; Csóka et al., 2018), anticancer (breast cancer, leukemia, glioblastoma, cervical cancer, gastric cancer, ovarian cancer, colon cancer, melanoma, and lung cancer; Crump, 2017). Multifaceted ‘wonder’ ivermectin may become an even more exceptional drug in the future. An international patent ‘Use of ivermectin and derivatives thereof’ caught people's increasing attention to ivermectin those years. Ivermectin would be developed to use for metabolic‐related diseases (diabetes, hypercholesterolemia, insulin resistance, obesity, hypertriglyceridemia, and hyperglycemia), Famesoid X receptor‐mediated diseases (atherosclerosis, nonalcohol fatty liver disease, cholestasia, and gallstones), inflammation, and cancer (Crump, 2017).